China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the China Drug Delivery Devices devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the Drug Delivery Devices in China

Scope

• The report provides drug delivery devices information broken down into detailed categories and segments in China.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

Reasons to buy

• Gain a strong understanding of the drug delivery devices market in China
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

1 Table Of Contents
1 Table Of Contents 2
1.1 List of Tables 12
1.2 List of Figures 15
2 Introduction 17
2.1 What Is This Report About? 17
2.2 Definitions 17
2.2.1 Drug delivery devices 17
2.2.1.1 Needle-free Injections 17
2.2.1.2 Inhalation Systems 17
2.2.1.3 Infusion Systems 18
3 Healthcare Sector Review 19
3.1 Healthcare Expenditure 19
3.2 Healthcare Infrastructure 20
3.2.1 Healthcare Personnel Data 21
3.2.2 Healthcare Facilities Data 22
3.3 Healthcare Policy 25
4 Drug Delivery Devices in China 26
4.1 Drug Delivery Devices Overall Revenues (2000-2012) 26
4.2 Drug Delivery Devices Overall Volume (2000-2012) 32
4.3 Drug Delivery Devices Company Shares (2005-2006) 35
5 Inhalation Systems in China 36
5.1 Inhalation Systems Overall Revenues (2000-2012) 36
5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012) 40
5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012) 42
5.2 Inhalation Systems Overall Volume (2000-2012) 44
5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012) 46
5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012) 48
5.3 Inhalation Systems Average Price (2000-2012) 50
5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012) 50
5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012) 52
5.4 Inhalation Systems Distribution Share (2005-2006) 54
5.5 Inhalation Systems Company Share (2005-2006) 55
6 Infusion Systems in China 56
6.1 Infusion Systems Overall Revenues (2000-2012) 56
6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012) 60
6.1.2 Syringe Pumps Overall Revenue (2000-2012) 62
6.1.3 Infusion Pumps Overall Revenues (2000-2012) 64
6.2 Infusion Systems Overall Volume (2000-2012) 66
6.2.1 Infusion Disposable Sets Overall Volume (2000-2012) 67
6.2.2 Syringe Pumps Overall Volume (2000-2012) 69
6.2.3 Infusion Pumps Overall Volume (2000-2012) 71
6.3 Infusion Systems Average Price (2000-2012) 73
6.3.1 Infusion Pumps Average Price (2000-2012) 73
6.3.2 Syringe Pumps Average Price (2000-2012) 75
6.3.3 Infusion Disposable Sets Average Price (2000-2012) 77
6.4 Infusion Systems Distribution Share (2005-2006) 79
6.5 Infusion Systems Company Share (2005-2006) 80
7 AstraZeneca PLC Company Profile 81
7.1 Company Overview 81
7.2 Business Overview 81
7.2.1 Products 83
7.2.2 History 84
7.3 Locations And Subsidiaries 85
7.4 Financial Deals Landscape 87
7.4.1 AstraZeneca Completes $6,900 Million Private Placement 87
7.4.2 AstraZeneca Acquires MedImmune 88
7.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics 90
7.4.4 AstraZeneca Acquires Arrow Therapeutics 91
7.4.5 AstraZeneca Signs An Agreement With Palatin Technologies 93
7.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb 94
7.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals 96
7.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical 97
7.4.9 Schering Signs An Agreement With AstraZeneca 99
7.4.10 AstraZeneca Signs An Agreement With Pozen 100
7.4.11 AstraZeneca Signs An Agreement With Abbott 101
7.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience 103
7.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals 104
7.4.14 AstraZeneca Acquires A Stake In Protherics 106
7.4.15 AstraZeneca Signs An Agreement With Targacept 108
7.4.16 AstraZeneca Signs An Agreement With AtheroGenics 109
7.4.17 AstraZeneca UK Signs An Agreement With Protherics 111
7.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft 112
7.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics 114
7.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals 115
7.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta 117
7.4.22 AstraZeneca Completes Private Placement Of $750 million 119
7.4.23 AstraZeneca Prices EUR750 Million Private Placement 120
7.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement 121
7.5 Recent Developments 123
7.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case 123
7.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director 123
7.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs 123
7.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO 124
7.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member 125
7.5.6 Jun 06, 2007: AstraZeneca CFO Resigns 125
7.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site 125
7.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development 126
7.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston 126
8 3M Company Profile 128
8.1 Company Overview 128
8.2 Business Overview 128
8.2.1 Consumer and Office 128
8.2.1.1 Overview 128
8.2.1.2 Capital Expenditure 128
8.2.1.3 Market View 128
8.2.1.4 Key Strategies 128
8.2.2 Display and Graphics 129
8.2.2.1 Overview 129
8.2.2.2 Financials 129
8.2.2.3 Capital Expenditure 129
8.2.2.4 Market View 129
8.2.2.5 Key Strategies 129
8.2.3 Electro and Communications 129
8.2.3.1 Overview 129
8.2.3.2 Financials 129
8.2.3.3 Capital Expenditure 129
8.2.3.4 Market View 130
8.2.3.5 Key Strategies 130
8.2.4 Health Care 130
8.2.4.1 Overview 130
8.2.4.2 Financials 130
8.2.4.3 Capital Expenditure 130
8.2.4.4 Market View 130
8.2.4.5 Key Strategies 131
8.2.5 Industrial and Transportation 131
8.2.5.1 Overview 131
8.2.5.2 Financials 131
8.2.5.3 Capital Expenditure 131
8.2.5.4 Market View 131
8.2.5.5 Key Strategies 131
8.2.6 Safety, Security and Protection Services 131
8.2.6.1 Overview 131
8.2.6.2 Financials 132
8.2.6.3 Capital Expenditure 132
8.2.6.4 Market View 132
8.2.6.5 Key Strategies 132
8.2.7 Products 132
8.3 Value Chain Analysis 134
8.3.1 Manufacturing 134
8.3.1.1 In House Manufacturing 134
8.3.2 Product Development 134
8.3.2.1 Regulatory Approvals 134
8.3.2.2 Clinical Trials 135
8.3.2.3 Research and Development 135
8.3.3 Sales and Marketing 135
8.3.3.1 Partnerships and Alliances 135
8.3.3.2 Licensing Agreements 135
8.3.3.3 E-distribution 135
8.4 SWOT Analysis 136
8.4.1 3M Company Strengths 136
8.4.1.1 Strong performance of Industrial and Transportation segment 136
8.4.1.2 Focused research and development 136
8.4.1.3 Decentralized operations 137
3M Company Weaknesses 137
8.4.1.4 Increased operating costs in the U.S. 137
8.4.1.5 Personal care segment’s poor performance 137
3M Company Opportunities 137
8.4.1.6 Expanding global presence 137
8.4.1.7 The liquid crystal display 137
8.4.1.8 Enhancing brand portfolio 138
3M Company Threats 138
8.4.1.9 Foreign currency fluctuations 138
8.4.1.10 Increasing cost of raw materials 138
8.4.1.11 Trend for private labels 138
8.5 Revenue Analysis 139
8.5.1 Revenue by Segment 139
8.5.2 Revenue by Geography 140
8.6 Financial and Operational Review 141
8.6.1 Financial Statements 141
8.6.2 Financial Ratios 142
8.7 Locations And Subsidiaries 143
8.8 Financial Deals Landscape 144
8.8.1 3M Canada Acquires Les Entreprises Solumed 144
8.8.2 3M Acquires Bondo 145
8.8.3 3M Acquires Lingualcare 147
8.8.4 3M Acquires Abzil Industria E Comercio 149
8.8.5 3M Acquires Neo Plast 151
8.8.6 3M Acquires Assets Of DMS Chile 153
8.8.7 3M Acquires Business Of Innovative Paper Technologies 155
8.8.8 3M Acquires Powell 157
8.8.9 Gen-Probe Signs An Agreement With 3M Company 159
8.8.10 3M Acquires Acolyte Biomedica 161
8.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp. 163
8.8.12 3M Sells Its Pharmaceutical Business To Meda AB 165
8.8.13 3M Acquires SoftMed Systems 167
8.8.14 3M Sells its Pharmaceuticals Business to Graceway 168
8.8.15 Gen-Probe Signs An Agreement With 3M 171
8.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital 173
8.8.17 3M Acquires Biotrace International 174
8.8.18 Ekahau Secures $16 Million In Additional Funding 176
8.8.19 3M Acquires Brontes Technologies 179
8.8.20 3M acquires Nylonge Corp 181
8.8.21 3M Signs An Agreement With ClozeX Medical 183
8.8.22 3M Acquires OMNII Oral Pharmaceuticals 185
8.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway 187
8.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB 189
8.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital 192
8.8.26 3M Acquires Accuspray Application Technologies Inc. 194
8.8.27 3M to acquire Rochford Thompson Equipment 196
8.8.28 3M To Acquire Aearo Technologies From Permira 198
8.8.29 Permira To Sell Aearo Technologies To 3M 200
8.9 Recent Developments 203
8.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses 203
8.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State 203
8.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia 205
8.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia 205
8.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year 205
8.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend 205
8.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery 205
8.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend 206
8.9.9 May 08, 2007: 3M Declares Quarterly Dividend 206
8.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests 206
9 Baxter International Company Profile 207
9.1 Company Overview 207
9.2 Business Overview 207
9.2.1 BioScience 207
9.2.1.1 Overview 207
9.2.1.2 Financials 207
9.2.1.3 Capital Expenditure 207
9.2.2 Medication Delivery 207
9.2.2.1 Overview 207
9.2.2.2 Financials 207
9.2.2.3 Capital Expenditure 208
9.2.3 Renal 208
9.2.3.1 Overview 208
9.2.3.2 Financials 208
9.2.3.3 Capital Expenditure 208
9.2.4 Products 209
9.2.5 History 210
9.3 Value Chain Analysis 213
9.3.1 Manufacturing 213
9.3.1.1 In House Manufacturing 213
9.3.2 Product Development 214
9.3.2.1 Regulatory Approvals 214
9.3.2.2 Clinical Trials 214
9.3.2.3 Research and Development 214
9.3.3 Sales and Marketing 215
9.3.3.1 Partnerships and Alliances 215
9.4 SWOT Analysis 216
9.4.1 Baxter International Inc. Strengths 216
9.4.1.1 Diversified geographic presence 216
9.4.1.2 Sturdy research and development activities 216
9.4.1.3 Strong financial performance 216
9.4.2 Baxter International Inc. Weaknesses 217
9.4.2.1 High levels of inventory 217
9.4.2.2 Decline in revenues of medication delivery 217
9.4.2.3 Reduced capital expenditure 217
9.4.3 Baxter International Inc. Opportunities 217
9.4.3.1 Co-developing alliances 217
9.4.3.2 Increasing End Stage Renal Disease patients 217
9.4.3.3 FDA approval 218
9.4.4 Baxter International Inc. Threats 218
9.4.4.1 Legal proceedings 218
9.4.4.2 Patent litigation 218
9.4.4.3 Stringent regulations 218
9.5 Revenue Analysis 219
9.5.1 Revenue by Segment 219
9.5.2 Revenue by Geography 220
9.6 Financial and Operational Review 221
9.6.1 Financial Statements 221
9.6.2 Financial Ratios 222
9.7 Locations And Subsidiaries 223
9.8 Financial Deals Landscape 225
9.8.1 Baiyunshan And Baxter Form A Joint Venture In China 225
9.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration 226
9.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital 228
9.8.4 B. Braun Acquires Renal Therapy Business Of Baxter 230
9.8.5 Innovata signs a license agreement with Baxter International 231
9.8.6 Kuros Biosurgery Signs An Agreement With Baxter International 233
9.8.7 Gambro Signs An Agreement With Baxter 234
9.8.8 Baxter Healthcare And Gambro Enter Into An Agreement 236
9.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System 237
9.8.10 Baxter International And Kaketsuken Enter Into Agreement 239
9.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful 240
9.9 Recent Developments 242
9.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007 242
9.9.2 Dec 18, 2007: Baxter Elects CFO 244
9.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend 244
9.9.4 Aug 01, 2007: Baxter Elects New Board Director 244
9.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend 245
9.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization 245
9.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend 245
9.9.8 Nov 28, 2006: Baxter Announces Annual Dividend 246
9.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America 246
9.10 Baxter International Inc. Pipeline Products 247
9.10.1 Next-Generation Home Hemodialysis Machine 247
9.10.1.1 Product Overview 247
9.10.1.2 Product Description 247
9.10.1.3 Product Status 247
9.10.1.4 Product Milestone 247
10 GlaxoSmithKline plc Company Profile 249
10.1 Company Overview 249
10.2 Business Overview 249
10.2.1 Products 250
10.2.2 History 250
10.3 Locations And Subsidiaries 253
10.4 Financial Deals Landscape 255
10.4.1 GlaxoSmithKline Acquires CNS 255
10.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline 256
10.4.3 CNS To Merge With GlaxoSmithKline 258
10.5 Recent Developments 260
10.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007 260
10.5.2 Feb 07, 2008: Full-year results announcement 2007 260
10.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance 260
10.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics 261
10.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes 262
11 Novartis AG Company Profile 263
11.1 Company Overview 263
11.2 Business Overview 263
11.2.1 Major Products and Services 264
11.3 Locations And Subsidiaries 265
11.4 Financial Deals Landscape 267
11.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis 267
11.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle 268
11.4.3 Novartis to sell Medical Nutrition business unit to Nestlé 270
11.4.4 Nestlé to Acquire Novartis Medical Nutrition 272
11.4.5 Novartis to sell its division Gerber Products Company to Nestle 273
12 Regulation System 276
12.1 Medical Equipment Approval Process 276
12.1.1 Classification 276
12.1.2 Registration and Conformity assessment 277
12.1.3 China Compulsory Certificate (CCC Mark) 279
12.1.4 Labeling and Packaging 280
12.1.5 Registration Fee 281
12.1.6 Registration Period 281
12.2 Post Market Surveillance (PMS) 281
13 Pricing and Reimbursement 282
14 Distribution Structure 284
15 APPENDIX 285
15.1 Global Markets Direct Research Methodology 285
15.2 Coverage 286
15.3 Secondary Research 286
15.4 Primary Research 287
15.5 Models 287
15.6 Forecasts 288
15.7 Expert Panels 288
15.8 Currency Conversion 289
15.9 Contact Us 290
15.10 Disclaimer 290


1.1 List of Tables
Table 1: Doctors by Specialty in China, 2003-2007 21
Table 2: Hospital Wards by Specialty in China, 2003 - 2007 22
Table 3: Healthcare Institutions in China, 2000-2004 23
Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2004 23
Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2004 24
Table 6: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012 26
Table 7: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 27
Table 8: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 28
Table 9: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012 29
Table 10: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007 30
Table 11: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012 31
Table 12: Drug Delivery Devices, China, Category Volume (Units), 2000-2012 32
Table 13: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007 33
Table 14: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012 34
Table 15: Drug Delivery Devices, China, Company Share by Revenue ($ mn), 2005-2006 35
Table 16: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007 36
Table 17: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012 37
Table 18: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007 38
Table 19: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012 39
Table 20: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 40
Table 21: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 41
Table 22: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 42
Table 23: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 43
Table 24: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007 44
Table 25: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012 45
Table 26: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007 46
Table 27: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012 47
Table 28: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007 48
Table 29: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012 49
Table 30: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007 50
Table 31: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012 51
Table 32: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007 52
Table 33: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012 53
Table 34: Inhalation Systems, China, Distribution Share by Revenue ($ mn), 2005-2006 54
Table 35: Inhalation Systems, China, Company Share by Revenue ($ mn), 2005-2006 55
Table 36: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007 56
Table 37: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012 57
Table 38: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007 58
Table 39: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012 59
Table 40: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007 60
Table 41: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012 61
Table 42: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007 62
Table 43: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012 63
Table 44: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007 64
Table 45: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012 65
Table 46: Infusion Systems, China, Overall Volume (Units), Historic, 2000-2007 66
Table 47: Infusion Systems, China, Overall Volume (Units), Forecast, 2007-2012 66
Table 48: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007 67
Table 49: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012 68
Table 50: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007 69
Table 51: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012 70
Table 52: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007 71
Table 53: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012 72
Table 54: Infusion Pumps, China, Average Price ($), Historic, 2000-2007 73
Table 55: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012 74
Table 56: Syringe Pumps, China, Average Price ($), Historic, 2000-2007 75
Table 57: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012 76
Table 58: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007 77
Table 59: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012 78
Table 60: Infusion Systems, China, Distribution Share by Revenue ($ mn), 2005-2006 79
Table 61: Infusion Systems, China, Company Share by Revenue ($ mn), 2005-2006 80
Table 62: AstraZeneca PLC, Subsidiaries 85
Table 63: AstraZeneca PLC, Subsidiaries(Contd..) 86
Table 64: 3M Company, SWOT Analysis, 2006 136
Table 65: 3M Company, Revenue by Segment, USD Million, 2003-2007 139
Table 66: 3M Company, Revenue by Geography, USD Million, 2003-2007 140
Table 67: 3M Company, Financial Statements, USD Million, 2003-2007 141
Table 68: 3M Company, Financial Ratios, USD Million, 2003-2007 142
Table 69: 3M Company, Subsidiaries 143
Table 70: Baxter International Inc., SWOT Analysis, 2006 216
Table 71: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007 219
Table 72: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007 220
Table 73: Baxter International Inc., Financial Statements, USD Million, 2003-2007 221
Table 74: Baxter International Inc., Financial Ratios, USD Million, 2003-2007 222
Table 75: Baxter International Inc., Other Locations 223
Table 76: Baxter International Inc., Subsidiaries 224
Table 77: GlaxoSmithKline plc, Subsidiaries 253
Table 78: GlaxoSmithKline plc, Subsidiaries(Contd..) 254
Table 79: Novartis Medical Nutrition, Other Locations 265
Table 80: Novartis Medical Nutrition, Other Locations(Contd..) 266
Table 81: Currency Conversion from USD to Local Currency at 2007 Constant Rate 289


1.2 List of Figures
Figure 1: Total Healthcare Expenditure in China, 2000 – 2005 20
Figure 2: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012 26
Figure 3: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 27
Figure 4: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 28
Figure 5: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012 29
Figure 6: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007 30
Figure 7: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012 31
Figure 8: Drug Delivery Devices, China, Category Volume (Units), 2000-2012 32
Figure 9: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007 33
Figure 10: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012 34
Figure 11: Drug Delivery Devices, China, Company Share (%), 2006 35
Figure 12: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007 36
Figure 13: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012 37
Figure 14: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007 38
Figure 15: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012 39
Figure 16: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 40
Figure 17: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 41
Figure 18: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 42
Figure 19: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 43
Figure 20: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007 44
Figure 21: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012 45
Figure 22: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007 46
Figure 23: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012 47
Figure 24: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007 48
Figure 25: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012 49
Figure 26: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007 50
Figure 27: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012 51
Figure 28: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007 52
Figure 29: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012 53
Figure 30: Inhalation Systems, China, Distribution Share (%), 2006 54
Figure 31: Inhalation Systems, China, Company Share (%), 2006 55
Figure 32: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007 56
Figure 33: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012 57
Figure 34: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007 58
Figure 35: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012 59
Figure 36: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007 60
Figure 37: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012 61
Figure 38: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007 62
Figure 39: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012 63
Figure 40: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007 64
Figure 41: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012 65
Figure 42: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007 67
Figure 43: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012 68
Figure 44: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007 69
Figure 45: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012 70
Figure 46: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007 71
Figure 47: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012 72
Figure 48: Infusion Pumps, China, Average Price ($), Historic, 2000-2007 73
Figure 49: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012 74
Figure 50: Syringe Pumps, China, Average Price ($), Historic, 2000-2007 75
Figure 51: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012 76
Figure 52: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007 77
Figure 53: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012 78
Figure 54: Infusion Systems, China, Distribution Share (%), 2006 79
Figure 55: Infusion Systems, China, Company Share (%), 2006 80
Figure 56: 3M Company, Value Chain Analysis 134
Figure 57: Baxter International Inc., Value Chain Analysis 213
Figure 58: Medical Equipment Registration Process in China, 2007 278
Figure 59: CCC Mark Certification Process in China, 2007 280
Figure 60: Global Markets Direct Methodology 285